Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study

Christian Brandt; Martin Schoendienst; Monika Trentowska; Mario Schrecke; Nora Fueratsch; Karin Witte-Boelt; Bernd Pohlmann-Eden; Theodor W. May

doi:10.1016/j.yebeh.2013.08.004

Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study

Christian Brandt, Martin Schoendienst, Monika Trentowska, Mario Schrecke, Nora Fueratsch, Karin Witte-Boelt, Bernd Pohlmann-Eden, Theodor W. May

Medicine

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Anxiety disorders are prevalent in people with epilepsy and severely influence daily living and quality of life. Pregabalin (PGB) is licensed in Germany for the add on-treatment of focal epilepsy and for generalized anxiety disorder in adults. To our knowledge, PGB has not been studied before in patients with epilepsy and comorbid anxiety disorder.We included 41 adult patients with focal epilepsy in a monocentric, noncontrolled open-label study adding up to 600. mg of PGB to an antiepileptic baseline medication. Patients were allocated to two groups: patients with epilepsy plus anxiety disorder (EAG) and patients with epilepsy only (EOG). Endpoints were responder rate, seizure frequency, adverse events, and anxiety symptoms.The responder rate in the EAG was higher compared to that in the EOG (per protocol population: 9 [75.0%] vs. 2 [12.5%], p. =0.001). Improvements in several psychological scales were found.

Original language	English
Pages (from-to)	298-304
Number of pages	7
Journal	Epilepsy and Behavior
Volume	29
Issue number	2
DOIs	https://doi.org/10.1016/j.yebeh.2013.08.004
Publication status	Published - Nov 2013

Bibliographical note

Funding Information:
TM has participated in research projects with unrestricted grants from Desitin , Eisai , GSK , Janssen-Cilag , Pfizer, Sanofi-Aventis , and UCB .

Funding Information:
CB served on scientific advisory boards for Eisai, Otsuka, UCB, and Pfizer; received funding for trips from UCB and Pfizer; received honoraria from serving on steering committees for Pfizer and Desitin and for being a speaker for Pfizer, Desitin, Eisai, UCB, and GSK; and received research support from Pfizer.

ASJC Scopus Subject Areas

Neurology
Clinical Neurology
Behavioral Neuroscience

Access to Document

10.1016/j.yebeh.2013.08.004

Cite this

Brandt, C., Schoendienst, M., Trentowska, M., Schrecke, M., Fueratsch, N., Witte-Boelt, K., Pohlmann-Eden, B., & May, T. W. (2013). Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study. Epilepsy and Behavior, 29(2), 298-304. https://doi.org/10.1016/j.yebeh.2013.08.004

Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study. / Brandt, Christian; Schoendienst, Martin; Trentowska, Monika et al.
In: Epilepsy and Behavior, Vol. 29, No. 2, 11.2013, p. 298-304.

Research output: Contribution to journal › Article › peer-review

Brandt, C, Schoendienst, M, Trentowska, M, Schrecke, M, Fueratsch, N, Witte-Boelt, K, Pohlmann-Eden, B & May, TW 2013, 'Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study', Epilepsy and Behavior, vol. 29, no. 2, pp. 298-304. https://doi.org/10.1016/j.yebeh.2013.08.004

@article{0308f37860d64424a6945d21fcf6948f,

title = "Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study",

abstract = "Anxiety disorders are prevalent in people with epilepsy and severely influence daily living and quality of life. Pregabalin (PGB) is licensed in Germany for the add on-treatment of focal epilepsy and for generalized anxiety disorder in adults. To our knowledge, PGB has not been studied before in patients with epilepsy and comorbid anxiety disorder.We included 41 adult patients with focal epilepsy in a monocentric, noncontrolled open-label study adding up to 600. mg of PGB to an antiepileptic baseline medication. Patients were allocated to two groups: patients with epilepsy plus anxiety disorder (EAG) and patients with epilepsy only (EOG). Endpoints were responder rate, seizure frequency, adverse events, and anxiety symptoms.The responder rate in the EAG was higher compared to that in the EOG (per protocol population: 9 [75.0%] vs. 2 [12.5%], p. =0.001). Improvements in several psychological scales were found.",

author = "Christian Brandt and Martin Schoendienst and Monika Trentowska and Mario Schrecke and Nora Fueratsch and Karin Witte-Boelt and Bernd Pohlmann-Eden and May, {Theodor W.}",

note = "Funding Information: TM has participated in research projects with unrestricted grants from Desitin , Eisai , GSK , Janssen-Cilag , Pfizer, Sanofi-Aventis , and UCB . Funding Information: CB served on scientific advisory boards for Eisai, Otsuka, UCB, and Pfizer; received funding for trips from UCB and Pfizer; received honoraria from serving on steering committees for Pfizer and Desitin and for being a speaker for Pfizer, Desitin, Eisai, UCB, and GSK; and received research support from Pfizer. ",

year = "2013",

month = nov,

doi = "10.1016/j.yebeh.2013.08.004",

language = "English",

volume = "29",

pages = "298--304",

journal = "Epilepsy and Behavior",

issn = "1525-5050",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study

AU - Brandt, Christian

AU - Schoendienst, Martin

AU - Trentowska, Monika

AU - Schrecke, Mario

AU - Fueratsch, Nora

AU - Witte-Boelt, Karin

AU - Pohlmann-Eden, Bernd

AU - May, Theodor W.

N1 - Funding Information: TM has participated in research projects with unrestricted grants from Desitin , Eisai , GSK , Janssen-Cilag , Pfizer, Sanofi-Aventis , and UCB . Funding Information: CB served on scientific advisory boards for Eisai, Otsuka, UCB, and Pfizer; received funding for trips from UCB and Pfizer; received honoraria from serving on steering committees for Pfizer and Desitin and for being a speaker for Pfizer, Desitin, Eisai, UCB, and GSK; and received research support from Pfizer.

PY - 2013/11

Y1 - 2013/11

N2 - Anxiety disorders are prevalent in people with epilepsy and severely influence daily living and quality of life. Pregabalin (PGB) is licensed in Germany for the add on-treatment of focal epilepsy and for generalized anxiety disorder in adults. To our knowledge, PGB has not been studied before in patients with epilepsy and comorbid anxiety disorder.We included 41 adult patients with focal epilepsy in a monocentric, noncontrolled open-label study adding up to 600. mg of PGB to an antiepileptic baseline medication. Patients were allocated to two groups: patients with epilepsy plus anxiety disorder (EAG) and patients with epilepsy only (EOG). Endpoints were responder rate, seizure frequency, adverse events, and anxiety symptoms.The responder rate in the EAG was higher compared to that in the EOG (per protocol population: 9 [75.0%] vs. 2 [12.5%], p. =0.001). Improvements in several psychological scales were found.

AB - Anxiety disorders are prevalent in people with epilepsy and severely influence daily living and quality of life. Pregabalin (PGB) is licensed in Germany for the add on-treatment of focal epilepsy and for generalized anxiety disorder in adults. To our knowledge, PGB has not been studied before in patients with epilepsy and comorbid anxiety disorder.We included 41 adult patients with focal epilepsy in a monocentric, noncontrolled open-label study adding up to 600. mg of PGB to an antiepileptic baseline medication. Patients were allocated to two groups: patients with epilepsy plus anxiety disorder (EAG) and patients with epilepsy only (EOG). Endpoints were responder rate, seizure frequency, adverse events, and anxiety symptoms.The responder rate in the EAG was higher compared to that in the EOG (per protocol population: 9 [75.0%] vs. 2 [12.5%], p. =0.001). Improvements in several psychological scales were found.

UR - http://www.scopus.com/inward/record.url?scp=84885066552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885066552&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2013.08.004

DO - 10.1016/j.yebeh.2013.08.004

M3 - Article

C2 - 24012505

AN - SCOPUS:84885066552

SN - 1525-5050

VL - 29

SP - 298

EP - 304

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

IS - 2

ER -

Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this